TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02346916
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
Study: NCT02716142
Drug: rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
Study: NCT02716142
Drug: sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
Study: NCT00864513
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
Study: NCT03160807
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levolet 500 mg OD for 5 days
Study: NCT03160807
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levolet 500 OD for 10 days
Study: NCT01783015
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50 mg once-weekly
Study: NCT01713738
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: infusion of 4 weekly doses of 375 mg/m2 rituximab
Study: NCT01297244
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Study: NCT00069329
Drug: anakinra
Normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: daily injection of subcutaneous injection
Study: NCT00263562
Drug: Steroid arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
Study: NCT00873756
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous repeating dose
Study: NCT00873756
Drug: dulanermin
Normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT02389348
Drug: OZ439
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of OZ439
Study: NCT04593563
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5 capsule oral psilocybin dose: 25mg: 5 x 5 mg capsules.
Study: NCT02349581
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01846871
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01482754
Drug: Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
Study: NCT02573727
Drug: Nor adrenaline + albumin
Normalized name: Nor-adrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02573727
Drug: Terlipressin + albumin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02728895
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab Injection.
Study: NCT00661219
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
Study: NCT01972178
Drug: Statins
Normalized name: Endostatins
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
Study: NCT00267319
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03212469
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses
Study: NCT03212469
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~* Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~* SBRT at C1D15, then~* Durvalumab Q4W alone for up to 9 additional doses
Study: NCT02985281
Drug: Sofosbuvir Oral Product
Normalized name: sofosbuvir Oral Product
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: direct acting antiviral drug for HCV infection
Study: NCT02985281
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: antiviral drug for HCV infection
Study: NCT05226000
Drug: Benaglutide Injection
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
Study: NCT00008268
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01901588
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
Study: NCT03676725
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel (0.75 g premeasured dose of Septodont 5% oral gel NDC 0362-0221-10)
Study: NCT00025311
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04224051
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin target dose 2 g daily
Study: NCT01406431
Drug: Pitavastatin, Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
Study: NCT03865680
Drug: Duraphat
Normalized name: testosterone enanthate Injectable Solution [Durathate]
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
Study: NCT02441114
Drug: HCP0910 and HGP1011
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
Study: NCT01691807
Drug: ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment for NHL
Study: NCT01691807
Drug: bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment for NHL
Study: NCT01691742
Drug: MiraLax
Normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
Study: NCT00272558
Drug: Carboplatin and Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02159690
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160mg
Study: NCT02159690
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000mg
Study: NCT02159690
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
Study: NCT02159690
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg
Study: NCT02159690
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
Study: NCT00050427
Drug: ET743
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
Study: NCT00050427
Drug: ET743
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
Study: NCT00937157
Drug: Copaxone
Normalized name: Copaxone
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
Study: NCT02734238
Drug: Sesame Oil
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
Study: NCT02734238
Drug: testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
Study: NCT01459614
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV on Days 4 and 11
Study: NCT00976391
Drug: insulin glargine + preprandial lispro insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: insulin glargine in combination with preprandial lispro insulin
Study: NCT01942291
Drug: Niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
Study: NCT02187250
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02187250
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02187250
Drug: roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01072812
Drug: Posiphen® tartrate capsules
DrugBank: Posiphen (DB15317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
Study: NCT01459614
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV on Days 4 and 11
Study: NCT01459614
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally, twice a day Days 1-14
Study: NCT01459614
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Days 4 and 11
Study: NCT01362374
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Study: NCT01362374
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Study: NCT01362374
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
Study: NCT01362374
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
Study: NCT01362374
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin at a dose level of 85 mg/m\^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Study: NCT01362374
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel at a dose of 90 mg/m\^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study: NCT01430156
Drug: Heme arginate (Normosang)
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
Study: NCT01430156
Drug: 0.9% sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
Study: NCT00132184
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00563212
Drug: aerosol interferon-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
Study: NCT01930747
Drug: rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: measure effect on laparoscopic workspace
Study: NCT01930747
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 MAC sevoflurane inhalation is given
Study: NCT01930747
Drug: remifentanyl
Normalized name: Remifentanyl
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanyl is given in infusion
Study: NCT03472469
Drug: Celebrex
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celebrex 200mg PO every 12 hours
Study: NCT03472469
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol 100mg PO every 6 hours
Study: NCT03472469
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 100mg PO every 8 hours
Study: NCT03472469
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 300mg PO every 8 hours
Study: NCT03472469
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine patch every 12 hours
Study: NCT03043027
Drug: liposomal bupivicaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthetic
Study: NCT03043027
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthetic
Study: NCT03043027
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline injection
Study: NCT02402543
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02402543
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
Study: NCT02402543
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
Study: NCT03179995
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
Study: NCT01220947
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Copegus 1000 mg or 1200 mg po daily for 24 weeks.
Study: NCT01220947
Drug: Danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 50 mg BID
Study: NCT01220947
Drug: Danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 100 mg BID
Study: NCT01220947
Drug: Danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 200 mg BID
Study: NCT01220947
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegasys 180 microgram sc qw
Study: NCT01220947
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 100 mg
Study: NCT02826031
Drug: Sodium Hyaluronate Injection
Normalized name: Sodium Hyaluronate Injection
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01342146
Drug: pegylated Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg/kg/wk once a week for 25 weeks
Study: NCT01342146
Drug: pegylated Somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 mg/kg/wk once a week for 25 weeks
Study: NCT00473642
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal administered ranibizumab 0.5 mg in 0.05 mL
Study: NCT00473642
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
Study: NCT00473642
Drug: Verteporfin
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
Study: NCT00022633
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00022633
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01132157
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
Study: NCT01132157
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.